Evidence map›Paper›PMID 40470730›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Single-Cell and Spatial Transcriptomic Profiling of Penile Squamous Cell Carcinoma Reveals Dynamics of Tumor Differentiation and Immune Microenvironment.

Hongjian Song, Zhichao Tong, Guixiang Xie, Yaowei Li, Yubo Zhao, Fengpu Fan, Zongzheng Yang, Qing Shi, Qian Zhang, Feng Wen and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Association of CCL21Cancer immunology, immunotherapy : CII · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Hongjian SongNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Zhichao TongNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Guixiang XieBGI Research, Chongqing, 401329, China.
Yaowei LiNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Yubo ZhaoNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Fengpu FanBGI Research, Beijing, 102601, China.
Zongzheng YangNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Qing ShiNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Qian ZhangBGI Research, Beijing, 102601, China.
Feng WenBGI Research, Beijing, 102601, China.
Hongxue MengDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Haonan LiNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Pengyu GuoNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Dayong HouNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Zhenwei ZhangNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Zhihao YinNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Ziyi LiuNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Jianwei WangNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Peng ZhangNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Peng DaiNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Changfu LiDepartment of Urology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Lichen TengDepartment of Urology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Yangyang XuDepartment of Urology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Dexin DingDepartment of Urology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Tao XuDepartment of Urology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Jianzhang LiDepartment of Urology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Yongsheng ChenDepartment of Urology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Yu QiuDepartment of Urology, Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
XiaoWei HuDepartment of Urogenital Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Wentao LiuDepartment of Urogenital Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Liang WuBGI Research, Chongqing, 401329, China.
Roman NawrothDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, 80333, Munich, Germany.
Guibo LiBGI Research, Chongqing, 401329, China.
Hang SuBGI Research, Beijing, 102601, China.
Ziqing DengBGI Research, Beijing, 102601, China.
Ziqi WangNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Di WangNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.ORCID 0009-0001-0371-010X
Wanhai XuNHC Key Laboratory of Molecular Probes and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.ORCID 0000-0003-3442-7988

Funding

Chun-Yan Innovation Team Program from Heilongjiang Provincial Department of Science and Technology CYQN24038Harbin Medical University Cancer Hospital Haiyan Foundation JJYQ2024-03Harbin Medical University Cancer Hospital Haiyan Foundation JJZD2024-05Harbin Medical University Cancer Hospital Haiyan Foundation JJZD2024-24Heilongjiang Provincial Department of Human Resources and Social Security LBH-Z22030Heilongjiang Provincial Postdoctoral Science Foundation 2021M693828Hong Kong scholar project XJ2024052Key Project of Heilongjiang Province Outstanding Young Teachers Basic Research YQJH2023034Key Research and Development Program of Heilongjiang Province 2022ZX06004Key Research and Development Program of Heilongjiang Province 2022ZXJ03C07National Key Research and Development Program of China 2021YFB3801000National Key Research and Development Program of China 2022YFA1103400National Natural Science Foundation of China 82171999National Natural Science Foundation of China 82302266National Natural Science Foundation of China 82402416Natural Science Foundation of Heilongjiang Province YQ2024H023Nn10 project at Harbin Medical University Cancer Hospital Nn102024-01Talent Support Program of Harbin Medical University 31021240077"Young Marshal Unveiling" Project of Harbin Medical University 31021240027
6 · The paper itself

Abstract

Penile squamous cell carcinoma (PSCC) is a highly aggressive malignancy without effective treatment due to limited knowledge of its development and tumor microenvironment (TME). In this study, single-nucleus RNA sequencing (snRNA-seq) and high-resolution spatial transcriptomics are employed to comprehensively investigate the development trajectories and the TME. The results revealed that PSCC cells mimicked the differentiation and tissue organization of normal penile epithelium, independent of the human papillomavirus (HPV) infection status. Notably, a spatial subtype, Tum_1, appeared at early stage of tumor differentiation and in tumor-normal boundary regions. This subtype exhibited enhanced basal-like and stemness features and showed high LAMC2 expression, which activated laminin-integrin signaling via ITGA6/ITGB4, promoting tumor invasiveness. Furthermore, the results indicated that HPV-positive basal stem-like neoplasms dampened the immune function of T cells and macrophages, promoting an immunosuppressive environment that facilitates tumor progression. Supporting this, the patients with head and neck squamous cell carcinoma and lung squamous cell carcinoma who have high expression of HPV-positive Tum_1 signatures derived greater benefit from PD-1 blockade therapy. In summary, the findings provide a comprehensive spatial landscape of the PSCC TME and suggest potential treatment approaches targeting laminin-integrin interaction and immunotherapy, especially in HPV-positive patients.

Indexed as

Carcinoma, Squamous CellPenile NeoplasmsTumor MicroenvironmentCell DifferentiationGene Expression ProfilingHumansMalePapillomavirus InfectionsSingle-Cell AnalysisTranscriptomepenile squamous cell carcinomasingle‐nucleus RNA sequencingspatial landscapespatial transcriptomicstumor microenvironment

Identifiers

PMID40470730
PMCPMC12412502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.